Aspire Biopharma Holdings, Inc. (ASBP) Form 8-K — Jun 12, 2026
Aspire Biopharma Holdings, Inc. (ASBP) has entered into a definitive Share Purchase Agreement to acquire 100% of Dura Driver Control Systems (DCS), a global automotive supplier, for $30 million in cash. The acquisition marks a strategic pivot for the biopharma company, adding a high-revenue industrial business with over $200 million in annual revenue and $22 million in Adjusted EBITDA. The transaction is expected to close in the third quarter of 2026, subject to customary conditions including a clean PCAOB audit of DCS’s financials for fiscal years 2024 and 2025.
Key figures
- Revenue
- 200000000
- Net Income
- 17000000
- Deal Value Usd
- 30000000
- Oem Customers
- 50
- Patents Owned
- 310
- Adjusted Ebitda
- 22000000
- Termination Fee
- 3500000
- Global Facilities
- 11
- Deferred Revenue Credit
- 800000
Price after filing
Close on the filing date to close N calendar days later (from $6.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.